Browsing by Author "Karadurmuş, Nuri"
Now showing items 1-9 of 9
-
Crizotinib efficacy in alk-positive advanced stage non-small cell lung cancer patients: A real-world experience from Turkey
Kılıçkap, Sadettin; Öztürk, Akın; Karadurmuş, Nuri; Korkmaz, Taner; Yumuk, Perran Fulden; Çiçin, İrfan; Paydaş, Semra; Çılbır, Ebru; Sakalar, Teoman; Uysal, Mükremin; Üskent, Necdet; Demir, Nurcan; Sakin, Ayşegül; Turhal, Nazım Serdar; Keskin, Serhat; Tural, Deniz; Eralp, Yeşim; Buğdaycı Başal, Fatma; Yaşar, Hatime Arzu; Sendur, Mehmet Ali Nahit; Demirci, Umut; Çubukçu, Erdem; Karaağaç, Mustafa; Karaca, Saziye; Tatlı, Ali Murat; Yetişyiğit, Tarkan; Urvay, Semiha; Gürsoy, Pınar; Oyan Uluç, Başak; Turna, Zeynep Hande; Küçüköner, Mehmet; Ölmez, Ömer Fatih; Çabuk, Devrim; Şeker, Mesut; Ünal, Olçun Umut; Meydan, Nezih; Okutur, Sadi Kerem; Tunalı, Duygu (Elsevier Science Inc, 2018)Background: Increasing evidence leads to a ratiocination that genetic heterogeneity of the lung adenocarcinoma patients with sensitive EGFR mutations may impact clinical responses and outcomes to EGFR-TKIs. Method: We ... -
Does primary tumor localization has prognostic importance in seminoma patients?: Turkish Oncology Group Study
Yıldız, Birol; Küçükarda, Ahmet; Gökyer, Ali; Demiray, Atike Gökçen; Paydaş, Semra; Aral, İpek Pınar; Gümüşay, Özge; Bilici, Ahmet; Akdeniz, Nadiye; Bahçeci, Aykut; Demir, Hacer; Esin, Ece; Üyetürk, Ümmügül; Ökten, İlker Nihat; Ertürk, İsmail; Türk, Hacı Mehmet; Topaloğlu, Ulaş Serkan; Başoğlu, Tuğba; Turhal, Nazım Serdar; Yeşil Çınkır, Havva; Menekşe, Serkan; Çakmak, Yağmur; Ürün, Yüksel; Acar, Ramazan; Kut, Engin; Dal, Pınar; Sakalar, Teoman; Aktepe, Oktay Halit; Karadurmuş, Nuri (Imprimatur Publications, 2020)Purpose: The purpose of this study was to determine whether primary tumor localization may be a risk factor for relapse and survival in seminomatous germ cell tumors (GCT) patients.Methods: In our study, 612 seminomatous ... -
The effect of primary surgery in patients with de novo stage IV breast cancer with bone metastasis only (Protocol BOMET MF 14-01): A multi-center, prospective registry study
Soran, Atilla; Doğan, Lütfi; Işık, Arda; Özbaş, Serdar; Can Trabulus, Didem; Demirci, Umut; Karanlık, Hasan; Soyder, Aykut; Dağ, Ahmet; Bilici, Ahmet; Doğan, Mutlu; Köksal, Hande; Şendur, Mehmet Ali Nahit; Gülçelik, Mehmet Ali; Maralcan, Göktürk; Cabıoğlu, Neslihan; Yeniay, Levent; Utkan, Zafer; Şimşek, Turgay; Karadurmuş, Nuri; Dağlar, Gül; Yıldız, Birol; Uras, Cihan; Tükenmez, Mustafa; Yıldırım, Ahmet; Kutun, Suat; Özaslan, Cihangir; Karaman, Niyazi; Akçay, Müfide Nuran; Toktaş, Osman; Sezgin, Efe (Springer, 2021)Background More evidence shows that primary surgery for de novo metastatic breast cancer (BC) prolongs overall survival (OS) in selected cases. The aim of this study was to evaluate the role of locoregional treatment (LRT) ... -
Is change in hemoglobin level a predictive biomarker of tyrosine kinase efficacy in metastatic renal cell carcinoma? A Turkish oncology group study
Bilir, Cemil; Yıldız, İbrahim; Bilici, Ahmet; Uçar, Mahmut; Berk, Veli; Yıldız, Yaşar; Yazıcı, Ozan; İnanç İmamoğlu, Gökşen; Karadurmuş, Nuri; Pilancı, Kezban Nur; Arpacı, Erkan; Tanrıverdi, Özgür; Karcı, Ebru; Temiz, Süleyman; Nayır, Erdinç; Oktay, Esin; Dal, Pınar; Petekkaya, İbrahim; Varım, Ceyhun; Cinemre, Hakan (Taylor & Francis Inc., 2017)Background: There are insufficient predictive markers for renal cell carcinoma (RCC). Methods: A total of 308 metastatic RCC patients were analyzed retrospectively. Results: The increased hemoglobin (Hb) group had significantly ... -
Nivolumab for relapsed or refractory hodgkin lymphoma experience in Turkey
Ferhanoğlu, Burhan; Beköz, Hüseyin Saffet; Karadurmuş, Nuri; Paydaş, Semra; Gülbaş, Zafer; Türker, Alev; Toptaş, Tayfur; Fıratlı Tuğlular, Tülin; Tekgündüz, Emre; Kaya, Ali Hakan; Taştemir, N.; Arat, Mutlu; Pepedil Tanrıkulu, Funda; Özkocaman, Vildan; Abalı, Hüseyin; Turgut, Mehmet; Kaynar, Leylagül; Karadoğan, İhsan; Özbalak, Murat; Özcan, Muhit; Doğu, Mehmet Hilmi; Kabukçu Hacıoğlu, Sibel; Yıldırım, Rahsan; Barışta, İbrahim; Demirkaya, Metin; Köseoğlu, Fatoş Dilan; Yüksel, Meltem Kurt; Sönmez, Mehmet; Toprak, Selami Koçak (Ferrata Storti Foundation, 2017)… -
Nivolumab for relapsed or refractory Hodgkin lymphoma: Real-life experience
Beköz, Hüseyin Saffet; Karadurmuş, Nuri; Paydaş, Semra; Türker, Alev; Toptaş, Tayfur; Fıratlı Tuğlular, Tülin; Sönmez, Mehmet Giray; Gülbaş, Zafer; Tekgündüz, Emre; Kaya, Ali Hakan; Özbalak, Murat; Taştemir, N; Kaynar, Leylagül; Yildirim Rahşan; Karadoğan, İhsan; Arat Ersöz, Mutlu; Pepedil Tanrıkulu, Funda; Özkocaman, Vildan; Abali, Hüseyin; Turgut, Mehmet; Kurt Yüksel, M; Özcan, Muhit; Doğu, Mehmet Hilmi; Kabukçu Hacıoğlu, Sibel; Barişta, İbrahim; Demirkaya, Metin; Köseoğlu, Fatoş Dilan; Toprak, Selami Koçak; Yilmaz, Mehmet Birhan; Demirkürek, Hüseyin; Demirkol, Mehmet Onur; Ferhanoğlu, Burhan (Oxford University Press, 2017)Background: Reed-Sternberg cells of classical Hodgkin's lymphoma (cHL) are characterized by genetic alterations at the 9p24.1 locus, leading to over-expression of programmed death-ligand 1 and 2. In a phase 1b study, ... -
Nivolumab for relapsed or refractory Hodgkin lymphoma: Real-life experience
Beköz, Hüseyin; Özbalak, Murat; Karadurmuş, Nuri; Paydaş, Semra; Türker, Alev; Toptaş, Tayfur; Fıratlı Tuğlular, Tülin; Altuntaş, Fevzi; Kızıl Çakar, Merih; Sönmez, Mehmet; Gülbaş, Zafer; Demir, Nazlı; Kaynar, Leylagül; Yıldırım, Rahşan; Karadoğan, İhsan; Arat, Mutlu; Kapucu, İrem; Alayvaz Aslan, Nevin; Özkocaman, Vildan; Turgut, Mehmet; Kurt Yüksel, Meltem; Özcan, Muhit; Kabukçu Hacıoğlu, Sibel; Barışta, İbrahim; Demirkaya, Metin; Saydam, Güray; Toprak, Selami Koçak; Yılmaz, Mehmet; Demirkol, Onur; Ferhanoğlu, Burhan (Springer, 2020)Classical Hodgkin lymphoma (cHL) is considered a curable disease; however, in approximately one-third of the responding patients, the disease relapses following completion of therapy. One of the drugs that have been approved ... -
Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naive breast cancer: Real-life practice outcomes
Esin, Ece; Çakmak Öksüzoǧlu, Berna; Bilici, Ahmet Erkan; Çiçin, İrfan; Köstek, Osman; Kaplan, Mehmet Ali; Aksoy, Sercan; Aktaş, Burak Yasin; Özdemir, Özlem; Alacacıoğlu, Ahmet; Çabuk, Devrim; Sümbül, Ahmet Taner; Sakin, Abdullah; Paydaş, Semra; Yetişir, Ersin; Er, Özlem; Korkmaz, Taner; Yıldırım, Nilgün; Şakalar, Teoman; Demir, Hacer; Artaç¸, Mehmet; Karaaǧaç, Mustafa; Harputluoǧlu, Hakan; Bilen, Ebru; Erdur, Erkan; Deǧirmencioǧlu, Serkan; Aliyev, Altay; Çil, Timuçin; Olgun, Polat; Başaran, Gül Atalay; Gümüşay, Özge; Demir, Atakan; Tanrıkulu, Eda; Yumuk, Perran Fulden; İmamoğlu, İnanç; Oyan, Başak; Çetin, Bülent Eren; Haksöyler, Veysel; Karadurmuş, Nuri; Ertürk, İsmail; Evrensel, Türkkan; Yılmaz, Hasan; Beypınar, İsmail; Koçer, Murat; Pilancı, Kezban Nur; Şeker, Mesut Metin; Ürün, Yüksel; Yıldırım, Nuriye O.; Eren, Tülay; Demirci, Umut (Springer, 2019)PurposeIn this study, we aimed to describe the real-life practice outcomes of pertuzumab-trastuzumab-taxane (PTT) combination in visceral organ metastatic, trastuzumab-naive breast cancer (BC) patients.MethodsThis study ... -
Prognostic factors for survival in metastatic renal cell carcinoma patients with brain metastases receiving targeted therapy
Yıldız, İbrahim; Bilici, Ahmet; Karadurmuş, Nuri; Özer, Leyla; Tural, Deniz; Kaplan, Mehmet Ali; Akman, Tülay; Bayoğlu, İbrahim Vedat; Uysal, Mükremin; Yıldız, Yaşar; Tanrıverdi, Özgür; Yazıcı, Ozan; Sürmeli, Zeki; Turhal, Nazim Serdar; Bavbek, Sevil; Selçukbiricik, Fatih; Koca, Doğan; Başaran, Mert (Sage Publications Ltd, 2018)Background: The primary objective of our study was to examine the clinical outcomes and prognosis of patients with metastatic renal cell carcinoma (mRCC) with brain metastases (BMs) receiving targeted therapy. Patients and ...
